Clinical trials · Nashville, TN
Solid Tumor, Adult clinical trials in Nashville
We’re tracking 48 recruiting solid tumor, adult studies with a site in or near Nashville — including Phase 1 and Phase 1/Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Nashville
- NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
Nashville, TennesseeAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Nashville, TennesseeAges 18 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT06326411RecruitingPhase 1
Testing NST-628 pills for advanced solid tumors with RAS/MAPK changes
This trial tests an experimental pill called NST-628 for people with advanced solid tumors that have specific genetic changes in the RAS/MAPK pathway. The goal is to see if it is safe and effective when other treatments are no longer working.
Nashville, TennesseeAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Nashville, TennesseeAges 18 years+ - NCT07205718RecruitingPhase 1/Phase 2
TAK-188 for advanced solid tumors after immunotherapy
This trial tests a new medication called TAK-188 for people with certain advanced solid tumors that have not responded to standard therapies, including checkpoint inhibitors. It aims to see if TAK-188 can help shrink or control the cancer.
Nashville, TennesseeAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT06108050RecruitingPhase 1
Testing a new drug alone and with pembrolizumab for advanced solid tumors
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT06644755RecruitingPhase 1
First-in-human study of DS-2243a for advanced cancers
This trial tests a new drug called DS-2243a for people with advanced solid tumors that have stopped responding to standard treatments. It targets a specific protein found in some cancers, and you need to have a particular immune system marker for it to work.
Nashville, TennesseeAges 18 years+ - NCT06415487RecruitingPhase 1
Testing a new cell therapy for advanced EGFR-positive solid tumors
This trial tests a new cell therapy called ACE2016 for people with advanced solid tumors that have EGFR on their surface. It may be an option if you have tried at least two other treatments (including a targeted therapy) and your cancer is still growing.
Nashville, TennesseeAges 18 years+ - NCT06398418RecruitingPhase 1
Study of R-5780 with PD-1 drugs for advanced solid tumors
This trial tests a new drug called R-5780 combined with standard immunotherapy (PD-1 checkpoint inhibitors) for people with advanced skin cancers or other solid tumors that have stopped responding to treatment. The goal is to see if this combination is safe and helps fight the cancer.
Nashville, TennesseeAges 18–80 - NCT07015697RecruitingPhase 1
Study of subcutaneous trastuzumab deruxtecan for advanced solid tumors
This trial tests a form of the drug trastuzumab deruxtecan that is given as a shot under the skin for people with certain metastatic solid tumors, including breast cancer and non-small cell lung cancer with HER2 changes. It aims to see how well the shot works and if it is safe.
Nashville, TennesseeAges 18 years+ - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Nashville, TennesseeAges 18 years+ - NCT05557045RecruitingPhase 1
Trial of an oral pill for MAPK-driven advanced solid tumors
This Phase 1 study tests an oral investigational medicine (JZP815) to see how safe it is, the best dose, and whether it can shrink tumors. It’s for adults with advanced or metastatic solid cancers that have a specific MAPK pathway genetic change.
Nashville, TennesseeAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Nashville, TennesseeAges 18 years+ - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Nashville, TennesseeAges 18 years+ - NCT05914116RecruitingPhase 1/Phase 2
Early study of DB-1311 with BNT324 for advanced solid tumors
This Phase 1/2a study tests a combination treatment (DB-1311 with BNT324) in people with advanced or metastatic solid cancers that have grown despite standard treatments. It aims to find a safe dose and look for signs the treatment can shrink tumors or slow growth.
Nashville, TennesseeAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Nashville, TennesseeAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Nashville, TennesseeAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Nashville, TennesseeAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Nashville, TennesseeAges 18 years+ - NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Nashville, TennesseeAges 18 years+
Hear when a new Solid Tumor, Adult trial opens near Nashville, TN
We’ll email you when one opens near Nashville, TN — at most once a week, no account needed, unsubscribe anytime.
Solid Tumor, Adult trials in other cities
Where these studies are running near Nashville
Institutions with a site for the recruiting solid tumor, adult studies listed above.
- Sarah Cannon Research Institute · 7 studies
- SCRI Oncology Partners · 6 studies
- Tennessee Oncology · 4 studies
- Vanderbilt University Medical Center · 4 studies
- Research Site · 3 studies
- Avenzo Therapeutics Recruiting Site
- Clinical Study Site
- SCRI
What taking part in a solid tumor, adult study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting solid tumor, adult studies in Tennessee.
Common questions
- Are there solid tumor, adult clinical trials near Nashville?
- Yes. We're currently tracking 48 recruiting solid tumor, adult studies with a site near Nashville, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumor, adult study near Nashville?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Nashville to take part?
- Not necessarily. These studies have a site near Nashville, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumor, adult trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumor, adult studies open near Nashville regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.